Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy

The presence of anti-E1E2 at treatment initiation is a predictive factor of SVR among patients treated with DAA and more likely among patients with low initial HCV viral load (< 6log10). Absence of anti-E1E2 at baseline could predict DAA-treatment failure.